Nothing Special   »   [go: up one dir, main page]

DK1248643T3 - Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi - Google Patents

Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi

Info

Publication number
DK1248643T3
DK1248643T3 DK01906631T DK01906631T DK1248643T3 DK 1248643 T3 DK1248643 T3 DK 1248643T3 DK 01906631 T DK01906631 T DK 01906631T DK 01906631 T DK01906631 T DK 01906631T DK 1248643 T3 DK1248643 T3 DK 1248643T3
Authority
DK
Denmark
Prior art keywords
cop
nervous system
cells
polypeptide
related peptide
Prior art date
Application number
DK01906631T
Other languages
English (en)
Inventor
Michal Eisenbach-Schwartz
Irun R Cohen
Michael Sela
Eti Yoles
Jonathan Kipnis
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK1248643T3 publication Critical patent/DK1248643T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK01906631T 2000-01-20 2001-01-22 Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi DK1248643T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48779300A 2000-01-20 2000-01-20
US20979900P 2000-06-07 2000-06-07
US62021600A 2000-07-20 2000-07-20

Publications (1)

Publication Number Publication Date
DK1248643T3 true DK1248643T3 (da) 2005-11-07

Family

ID=27395416

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01906631T DK1248643T3 (da) 2000-01-20 2001-01-22 Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi

Country Status (16)

Country Link
US (2) US6844314B2 (da)
EP (1) EP1248643B1 (da)
JP (1) JP4328050B2 (da)
KR (1) KR100822695B1 (da)
CN (1) CN100360180C (da)
AT (1) ATE302020T1 (da)
AU (1) AU780188B2 (da)
CA (1) CA2397785C (da)
DE (1) DE60112718T2 (da)
DK (1) DK1248643T3 (da)
ES (1) ES2243450T3 (da)
HK (1) HK1054507B (da)
IL (2) IL150800A0 (da)
MX (1) MXPA02007106A (da)
PT (1) PT1248643E (da)
WO (1) WO2001052878A2 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
CA2336238A1 (en) * 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2005046719A1 (en) * 2003-11-12 2005-05-26 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
CA2397785C (en) * 2000-01-20 2009-01-13 Michal Eisenbach-Schwartz The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
CA2411536A1 (en) * 2000-06-05 2001-12-13 V. Wee Yong The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
AU6887101A (en) * 2000-06-20 2002-01-02 Caprion Pharmaceuticals, Inc. Copolymers and methods of treating prion-related diseases
IL162127A0 (en) 2001-12-04 2005-11-20 Teva Pharma Process for the measurement of the potency of glatiramer acetate
CN1617736A (zh) * 2001-12-06 2005-05-18 耶达研究及发展有限公司 治疗运动神经元疾病的疫苗和方法
CN1758922A (zh) * 2003-01-07 2006-04-12 耶达研究及发展有限公司 用于治疗性免疫接种的含共聚物1的滴眼用疫苗
US20070197424A1 (en) * 2003-09-16 2007-08-23 Friedman Scott L Glatiramer acetate for use as an immuno-modulatory agent
DK1701730T3 (da) 2003-12-09 2013-11-25 Yeda Res & Dev Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser
BRPI0508382A (pt) * 2004-03-01 2007-07-31 Peptimmune Inc métodos e composições para tratamento de doenças auto-imunes
JP2007535498A (ja) * 2004-03-03 2007-12-06 テバ ファーマシューティカル インダストリーズ リミティド グラチラマー・アセテートおよびリルゾールでの併用療法
AU2005251686B2 (en) * 2004-05-07 2011-09-08 Ares Trading S.A. Methods of treating disease with random copolymers
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
SG153871A1 (en) * 2004-06-25 2009-07-29 Id Biomedical Corp Quebec Compositions and methods for treating neurological disorders
GB2431314B (en) * 2004-08-10 2008-12-24 1 Ltd Non-planar transducer arrays
US7560100B2 (en) * 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
DK2177528T3 (da) 2004-09-09 2012-03-26 Teva Pharma Fremgangsmåde til fremstilling af blandinger af trifluoracetylglatirameracetat ved anvendelse af oprenset hydrogenbromid
CA2583589C (en) * 2004-10-29 2012-04-24 Sandoz Ag Processes for preparing glatiramer
WO2006057003A2 (en) * 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Induction of neurogenesis and stem cell therapy in combination with copolymer 1
CA2594022A1 (en) * 2005-02-02 2006-08-10 Teva Pharmaceutical Industries Ltd. Process for producing polypeptide mixtures using hydrogenolysis
RS52867B (en) * 2005-02-17 2013-12-31 Teva Pharmaceutical Industries Ltd. GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
EP1891233A4 (en) * 2005-04-25 2010-03-24 Yeda Res & Dev MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US8378072B2 (en) 2006-04-13 2013-02-19 Declion Pharmaceuticals, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
KR100831796B1 (ko) * 2006-05-29 2008-05-28 엘지전자 주식회사 타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
US9089509B2 (en) * 2006-06-28 2015-07-28 Yeda Research And Development Co., Ltd. Method of treatment of age-related macular degeneration
WO2009040814A1 (en) 2007-09-24 2009-04-02 Hadasit Medical Research Services & Development Ltd Use of copolymer 1 for treatment of muscular dystrophy
KR20170075026A (ko) 2007-10-16 2017-06-30 펩팀문, 인코포레이티드 에피토프의 지정 확장에 의해 지정 서열 중합체 조성물을 포함하는 백신을 설계하고 제조하는 방법
EA201070656A1 (ru) * 2007-11-28 2010-12-30 Тева Фармасьютикал Индастриз, Лтд. Способ задержки начала проявления клинически определенного рассеянного склероза
ES2449865T5 (es) 2008-04-16 2022-11-18 Momenta Pharmaceuticals Inc Análisis de composiciones de copolímeros de aminoácidos
LT3199172T (lt) 2009-08-20 2018-10-25 Yeda Research And Development Co., Ltd. Dozavimo režimas, skirtas išsėtinei sklerozei
MX2020003805A (es) 2010-01-04 2022-05-05 Mapi Pharma Ltd Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo.
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
JP5904953B2 (ja) * 2010-03-10 2016-04-20 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Ａｌｓの早期診断およびａｌｓ進行のための細胞性血液マーカー
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EP2412802A1 (en) * 2010-07-29 2012-02-01 TXCell IL-13 producing TR1-like cells and use thereof
PT2627669T (pt) 2010-10-11 2016-11-24 Teva Pharma Biomarcadores de citocina como biomarcadores preditivos de resposta clínica para acetato de glatirâmero
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
WO2013055683A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
KR20140145173A (ko) * 2012-03-26 2014-12-22 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커
EP2892353A4 (en) 2012-09-10 2016-10-26 Yeda Res & Dev INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA
JP6149831B2 (ja) * 2014-09-04 2017-06-21 信越化学工業株式会社 シリコーン組成物
EP3370791A1 (en) 2015-11-03 2018-09-12 Ariel-University Research and Development Company Ltd. Compositions for regeneration and repair of neural tissue
CN109600992A (zh) * 2016-05-20 2019-04-09 西达-赛奈医疗中心 治疗或预防阿尔茨海默病和相关病况的方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
IL265099B2 (en) * 2016-09-02 2024-09-01 Christopher J Soares Medicinal compositions containing an effective amount of a calcitonin gene-related peptide (CGRP) receptor antagonist, or a pharmaceutically acceptable salt thereof, for the treatment of glaucoma
JP2020515530A (ja) 2017-03-26 2020-05-28 マピ ファーマ リミテッド 進行型の多発性硬化症を治療するためのグラチラマーデポシステム
WO2018211498A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
AU2017414803A1 (en) 2017-05-15 2019-12-05 Mapi Pharma Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
CN114790475A (zh) * 2021-01-25 2022-07-26 首都医科大学附属北京天坛医院 一种与亨廷顿病相关的肠道微生物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
WO1999041247A1 (en) * 1998-02-13 1999-08-19 Autoimmune, Inc. TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
CA2397785C (en) * 2000-01-20 2009-01-13 Michal Eisenbach-Schwartz The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy

Also Published As

Publication number Publication date
JP2003520246A (ja) 2003-07-02
AU780188B2 (en) 2005-03-03
CA2397785A1 (en) 2001-07-26
HK1054507B (zh) 2008-10-31
ES2243450T3 (es) 2005-12-01
EP1248643B1 (en) 2005-08-17
HK1054507A1 (en) 2003-12-05
JP4328050B2 (ja) 2009-09-09
CN100360180C (zh) 2008-01-09
DE60112718T2 (de) 2006-06-29
US7407936B2 (en) 2008-08-05
WO2001052878A9 (en) 2002-10-17
KR20020081266A (ko) 2002-10-26
ATE302020T1 (de) 2005-09-15
WO2001052878A8 (en) 2003-12-24
WO2001052878A3 (en) 2002-01-24
PT1248643E (pt) 2005-10-31
US6844314B2 (en) 2005-01-18
AU3451701A (en) 2001-07-31
CN1427726A (zh) 2003-07-02
DE60112718D1 (de) 2005-09-22
KR100822695B1 (ko) 2008-04-17
WO2001052878A2 (en) 2001-07-26
US20030004099A1 (en) 2003-01-02
CA2397785C (en) 2009-01-13
IL150800A (en) 2007-10-31
EP1248643A2 (en) 2002-10-16
US20050159336A1 (en) 2005-07-21
MXPA02007106A (es) 2002-12-13
IL150800A0 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
DK1248643T3 (da) Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi
DK1294390T3 (da) Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet
WO1999060021A3 (en) Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
DE69630890D1 (de) Peptid-immitierende substanzen in der krebstherapie
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE265213T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
TR199802421T2 (xx) Doku yenilenmesini d�zenleyen maddeler.
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
WO2002029087A3 (en) Use of lymphangiogenic agents to treat lymphatic disorders
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
ATE419875T1 (de) Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
WO2003103573A3 (en) METHODS OF TREATING A NEUROLOGICAL DISORDER BY PERIPHERAL DELIVERY OF A TROPHIC FACTOR
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
WO2005094497A3 (en) Systemic delivery of therapeutics to central nervous system
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
TH68405A (th) การบำบัดรักษามะเร็งเซลล์ไต
RU2003115786A (ru) Способ лечения пневмонии у новорожденных
EA200000514A1 (ru) Способ лечения эректильной дисфункции
RU97121459A (ru) Способ лечения эндокринных нарушений голоса
RU99124389A (ru) Способ лечения вегетососудистой дистонии